1. Male or female =18 years of age. 2. Individuals or their witnesses in case of illiteracy are willing and able to comply with study requirements, including all scheduled visits, vaccinations, laboratory tests, and other study procedures. 3. Individuals are willing and able to give an informed consent, prior to screening. 4. Female participants of childbearing potential may be enrolled in the study if the participant has practiced adequate contraception using a highly effective licensed method of birth control for 30 days prior to the first vaccination and has a negative pregnancy test on the day of vaccination and must agree to continue such precautions during until 90 days after the last vaccination. 5. Male participants must agree to employ acceptable contraception from the day of first dose of the study vaccine/comparator until 6 months after the first dose of the study vaccine/comparator and refrain from donating sperm during this period. 6. For HIV infected participants: individuals should be in general good health except stable HIV infection receiving a stable ART treatment for at least 6 months (defined as no change because of virological or immunological failure) and to have a CD4+ T-cell count > 200 cells/mm3 and a HIV RNA load of =50 copies/mL at screening.

1. Male or female =18 years of age. 2. Individuals or their witnesses in case of illiteracy are willing and able to comply with study requirements, including all scheduled visits, vaccinations, laboratory tests, and other study procedures. 3. Individuals are willing and able to give an informed consent, prior to screening. 4. Female participants of childbearing potential may be enrolled in the study if the participant has practiced adequate contraception using a highly effective licensed method of birth control for 30 days prior to the first vaccination and has a negative pregnancy test on the day of vaccination and must agree to continue such precautions during until 90 days after the last vaccination. 5. Male participants must agree to employ acceptable contraception from the day of first dose of the study vaccine/comparator until 6 months after the first dose of the study vaccine/comparator and refrain from donating sperm during this period. 6. For HIV infected participants: individuals should be in general good health except stable HIV infection receiving a stable ART treatment for at least 6 months (defined as no change because of virological or immunological failure) and to have a CD4+ T-cell count > 200 cells/mm3 and a HIV RNA load of =50 copies/mL at screening.